Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Hartung HP, et al. Among authors: kremer d. Mult Scler. 2022 Mar;28(3):429-440. doi: 10.1177/13524585211024997. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240656 Free article. Clinical Trial.
p57 kip2's role beyond Schwann cell cycle control.
Heinen A, Kremer D, Hartung HP, Küry P. Heinen A, et al. Among authors: kremer d. Cell Cycle. 2008 Sep 15;7(18):2781-6. doi: 10.4161/cc.7.18.6629. Epub 2008 Sep 16. Cell Cycle. 2008. PMID: 18769142
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Torres KJ, Göttle P, Kremer D, Rivera JF, Aguirre-Cruz L, Corona T, Hartung HP, Küry P. Torres KJ, et al. Among authors: kremer d. Cell Physiol Biochem. 2012;30(3):711-22. doi: 10.1159/000341451. Epub 2012 Aug 1. Cell Physiol Biochem. 2012. PMID: 22854710
286 results